Your Vanguard CRO and Translational Partner

Our Preclinical Neuropharmacology division delivers comprehensive CNS drug discovery services from target validation through IND-enabling studies. With HPRA-accredited facilities in Ireland and AAALAC-accredited platforms in North America, we provide fully validated behavioural assays, in vivo electrophysiology, and integrated PK/PD capabilities across rodent and canine species. Our portfolio includes validated depression models (IFN-α, Wistar Kyoto, Chronic Social Defeat), anxiety and cognition testing, and seizure susceptibility platforms for epilepsy and developmental encephalopathies. State-of-the-art EEG systems—tethered, wireless, and video-synchronised—capture translational biomarkers including sleep architecture, gamma oscillations, and auditory evoked potentials. Whether developing small molecules, biologics, or psychedelic therapeutics, our experienced neuroscientists accelerate your programme from concept to clinic.

Our Translational Medicine division bridges preclinical research and clinical development through advanced biomarker discovery, human iPSC-derived neuronal models, and global clinical biocollection capabilities. Our Cherrywood laboratory houses all major platforms under one roof—Luminex 200, MSD QuickPlex SQ 120MM, and Li-Cor Odyssey CLx—enabling ultra-sensitive quantification of neurodegeneration markers (Tau, pTau, GFAP, neurofilament light chain), neuroinflammation panels, and synaptic proteins across human, rodent, and canine samples. Clinical biomarker services span regulatory setup to HPRA-approved biobanking, supported by collaborations including San Raffaele Hospital and the ELPIS study. Our cell culture platform offers primary rodent neurons and iPSC-derived models—including Parkinson’s disease and CDKL5 deficiency lines—for neuroprotection assays and mechanistic studies. This integrated approach ensures direct comparability between preclinical findings and clinical endpoints.